

=> file hcaplus

FILE 'HCAPLUS' ENTERED AT 16:23:46 ON 26 MAR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Mar 2004 VOL 140 ISS 14

FILE LAST UPDATED: 25 Mar 2004 (20040325/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 138

```
L22      6 SEA FILE=REGISTRY ABB=ON (123-03-5/BI OR 56-81-5/BI OR
        57-55-6/BI OR 16969-45-2/BI OR 25322-68-3/BI OR 64-17-5/BI)
L23      1 SEA FILE=REGISTRY ABB=ON L22 AND 1/CL
L24      1 SEA FILE=REGISTRY ABB=ON "PROPYLENE GLYCOL"/CN
L26      4203 SEA FILE=HCAPLUS ABB=ON L23
L27      21616 SEA FILE=HCAPLUS ABB=ON L24
L28      120 SEA FILE=HCAPLUS ABB=ON L26 AND L27
L30      3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (AMMONIUM
        OR ?PYRIDIN? OR QAC)
L33      1 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) 40
L34      4 SEA FILE=HCAPLUS ABB=ON L30 OR L33
L35      0 SEA FILE=HCAPLUS ABB=ON L28 AND 40 (4A) (AMMONIUM OR ?PYRIDIN?
        OR QAC)
L36      3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (40 OR 41
        OR 42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)
L37      6 SEA FILE=HCAPLUS ABB=ON (L33 OR L34 OR L35 OR L36)
L38      6 SEA FILE=HCAPLUS ABB=ON L30 OR L37
```

=> file wpix

FILE 'WPIX' ENTERED AT 16:23:59 ON 26 MAR 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE LAST UPDATED: 24 MAR 2004 <20040324/UP>

MOST RECENT DERWENT UPDATE: 200420 <200420/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:

[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

KATHLEEN FULLER EIC 1700 REMSEN 4B28 571/272-2505

<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> ADDITIONAL POLYMER INDEXING CODES WILL BE IMPLEMENTED FROM  
DERWENT UPDATE 200403.  
THE TIME RANGE CODE WILL ALSO CHANGE FROM 018 TO 2004.  
SDIS USING THE TIME RANGE CODE WILL NEED TO BE UPDATED.  
FOR FURTHER DETAILS: <http://thomsonderwent.com/chem/polymers/> <<<

=> d que 148  
L39 20665 SEA FILE=WPIX ABB=ON PROPYLENE GLYCOL# OR PROPANEDIOL  
L45 583 SEA FILE=WPIX ABB=ON CETYL(W) PYRIDINIUM(W) CHLORIDE OR  
CETYLPYRIDINIUM CHLORIDE  
L46 27 SEA FILE=WPIX ABB=ON L45 AND (WEIGHT? OR WT) (4A) (40 OR 41 OR  
42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
L48 4 SEA FILE=WPIX ABB=ON L39 AND L46

=> file biosis  
FILE 'BIOSIS' ENTERED AT 16:24:11 ON 26 MAR 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE COVERS 1969 TO DATE.  
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 24 March 2004 (20040324/ED)

FILE RELOADED: 19 October 2003.

=> d que 151  
L22 6 SEA FILE=REGISTRY ABB=ON (123-03-5/BI OR 56-81-5/BI OR  
57-55-6/BI OR 16969-45-2/BI OR 25322-68-3/BI OR 64-17-5/BI)  
L23 1 SEA FILE=REGISTRY ABB=ON L22 AND 1/CL  
L24 1 SEA FILE=REGISTRY ABB=ON "PROPYLENE GLYCOL"/CN  
L26 4203 SEA FILE=HCAPLUS ABB=ON L23  
L27 21616 SEA FILE=HCAPLUS ABB=ON L24  
L28 120 SEA FILE=HCAPLUS ABB=ON L26 AND L27  
L30 3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (AMMONIUM  
OR ?PYRIDIN? OR QAC)  
L33 1 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) 40  
L34 4 SEA FILE=HCAPLUS ABB=ON L30 OR L33  
L35 0 SEA FILE=HCAPLUS ABB=ON L28 AND 40 (4A) (AMMONIUM OR ?PYRIDIN?  
OR QAC)  
L36 3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (40 OR 41  
OR 42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
L37 6 SEA FILE=HCAPLUS ABB=ON (L33 OR L34 OR L35 OR L36)  
L39 20665 SEA FILE=WPIX ABB=ON PROPYLENE GLYCOL# OR PROPANEDIOL  
L45 583 SEA FILE=WPIX ABB=ON CETYL(W) PYRIDINIUM(W) CHLORIDE OR  
CETYLPYRIDINIUM CHLORIDE  
L46 27 SEA FILE=WPIX ABB=ON L45 AND (WEIGHT? OR WT) (4A) (40 OR 41 OR  
42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
L49 0 SEA FILE=BIOSIS ABB=ON L30 OR L37  
L50 0 SEA FILE=BIOSIS ABB=ON L39 AND L46

KATHLEEN FULLER EIC 1700 REMSEN 4B28 571/272-2505

L51 0 SEA FILE=BIOSIS ABB=ON L49 OR L50

=> file medline

FILE 'MEDLINE' ENTERED AT 16:24:24 ON 26 MAR 2004

FILE LAST UPDATED: 25 MAR 2004 (20040325/UP). FILE COVERS 1951 TO DATE.

On February 29, 2004, the 2004 MeSH terms were loaded. See HELP RLOAD for details. OLD MEDLINE now back to 1951.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2004 vocabulary. See <http://www.nlm.nih.gov/mesh/> and [http://www.nlm.nih.gov/pubs/techbull/nd03/nd03\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd03/nd03_mesh.html) for a description of changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 152

L22 6 SEA FILE=REGISTRY ABB=ON (123-03-5/BI OR 56-81-5/BI OR 57-55-6/BI OR 16969-45-2/BI OR 25322-68-3/BI OR 64-17-5/BI)  
 L23 1 SEA FILE=REGISTRY ABB=ON L22 AND 1/CL  
 L24 1 SEA FILE=REGISTRY ABB=ON "PROPYLENE GLYCOL"/CN  
 L26 4203 SEA FILE=HCAPLUS ABB=ON L23  
 L27 21616 SEA FILE=HCAPLUS ABB=ON L24  
 L28 120 SEA FILE=HCAPLUS ABB=ON L26 AND L27  
 L30 3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (AMMONIUM OR ?PYRIDIN? OR QAC)  
 L33 1 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) 40  
 L34 4 SEA FILE=HCAPLUS ABB=ON L30 OR L33  
 L35 0 SEA FILE=HCAPLUS ABB=ON L28 AND 40 (4A) (AMMONIUM OR ?PYRIDIN? OR QAC)  
 L36 3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
 L37 6 SEA FILE=HCAPLUS ABB=ON (L33 OR L34 OR L35 OR L36)  
 L39 20665 SEA FILE=WPIX ABB=ON PROPYLENE GLYCOL# OR PROPANEDIOL  
 L45 583 SEA FILE=WPIX ABB=ON CETYL(W)PYRIDINIUM(W)CHLORIDE OR CETYLPYRIDINIUM CHLORIDE  
 L46 27 SEA FILE=WPIX ABB=ON L45 AND (WEIGHT? OR WT) (4A) (40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
 L49 0 SEA FILE=BIOSIS ABB=ON L30 OR L37  
 L50 0 SEA FILE=BIOSIS ABB=ON L39 AND L46  
 L52 0 SEA FILE=MEDLINE ABB=ON L49 OR L50

=> file embase

FILE 'EMBASE' ENTERED AT 16:24:42 ON 26 MAR 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE COVERS 1974 TO 25 Mar 2004 (20040325/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 167

KATHLEEN FULLER EIC 1700 REMSEN 4B28 571/272-2505

L22 6 SEA FILE=REGISTRY ABB=ON (123-03-5/BI OR 56-81-5/BI OR  
57-55-6/BI OR 16969-45-2/BI OR 25322-68-3/BI OR 64-17-5/BI)  
L23 1 SEA FILE=REGISTRY ABB=ON L22 AND 1/CL  
L24 1 SEA FILE=REGISTRY ABB=ON "PROPYLENE GLYCOL"/CN  
L26 4203 SEA FILE=HCAPLUS ABB=ON L23  
L27 21616 SEA FILE=HCAPLUS ABB=ON L24  
L28 120 SEA FILE=HCAPLUS ABB=ON L26 AND L27  
L30 3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (AMMONIUM  
OR ?PYRIDIN? OR QAC)  
L33 1 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) 40  
L34 4 SEA FILE=HCAPLUS ABB=ON L30 OR L33  
L35 0 SEA FILE=HCAPLUS ABB=ON L28 AND 40 (4A) (AMMONIUM OR ?PYRIDIN?  
OR QAC)  
L36 3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (40 OR 41  
OR 42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
L37 6 SEA FILE=HCAPLUS ABB=ON (L33 OR L34 OR L35 OR L36)  
L39 20665 SEA FILE=WPIX ABB=ON PROPYLENE GLYCOL# OR PROPANEDIOL  
L40 825 SEA FILE=WPIX ABB=ON CETYL(W)PYRIDINIUM(W)CHLORIDE OR  
CETYL PYRIDINIUM CHLORIDE OR CPC  
L41 57 SEA FILE=WPIX ABB=ON L39 AND L40  
L45 583 SEA FILE=WPIX ABB=ON CETYL(W)PYRIDINIUM(W)CHLORIDE OR  
CETYL PYRIDINIUM CHLORIDE  
L46 27 SEA FILE=WPIX ABB=ON L45 AND (WEIGHT? OR WT) (4A) (40 OR 41 OR  
42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
L49 0 SEA FILE=BIOSIS ABB=ON L30 OR L37  
L50 0 SEA FILE=BIOSIS ABB=ON L39 AND L46  
L52 0 SEA FILE=MEDLINE ABB=ON L49 OR L50  
L53 0 SEA FILE=MEDLINE ABB=ON L41 AND (WT OR WEIGHT?)  
L54 0 SEA FILE=MEDLINE ABB=ON L28 AND (WEIGHT? OR WT)  
L56 1 SEA FILE=EMBASE ABB=ON (L52 OR L53 OR L54)  
L57 854 SEA FILE=EMBASE ABB=ON L26 OR (L39 AND L45)  
L58 43 SEA FILE=EMBASE ABB=ON L57 AND DRUG COMBINATION/CT  
L61 853 SEA FILE=EMBASE ABB=ON CETYL PYRIDINIUM SALT+NT/CT  
L62 30 SEA FILE=EMBASE ABB=ON L61(L)CB/CT  
L63 30 SEA FILE=EMBASE ABB=ON L58 AND L62  
L64 1 SEA FILE=EMBASE ABB=ON L63 AND L24  
L65 1 SEA FILE=EMBASE ABB=ON L63 AND L39  
L66 1 SEA FILE=EMBASE ABB=ON L64 OR L65  
L67 1 SEA FILE=EMBASE ABB=ON L56 OR L66

=> file japio

FILE 'JAPIO' ENTERED AT 16:24:55 ON 26 MAR 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE LAST UPDATED: 1 MAR 2004 <20040301/UP>  
FILE COVERS APR 1973 TO OCTOBER 31, 2003

<<< GRAPHIC IMAGES AVAILABLE >>>

=> d que 170

L22 6 SEA FILE=REGISTRY ABB=ON (123-03-5/BI OR 56-81-5/BI OR  
57-55-6/BI OR 16969-45-2/BI OR 25322-68-3/BI OR 64-17-5/BI)  
L23 1 SEA FILE=REGISTRY ABB=ON L22 AND 1/CL  
L24 1 SEA FILE=REGISTRY ABB=ON "PROPYLENE GLYCOL"/CN  
L26 4203 SEA FILE=HCAPLUS ABB=ON L23  
L27 21616 SEA FILE=HCAPLUS ABB=ON L24  
L28 120 SEA FILE=HCAPLUS ABB=ON L26 AND L27

KATHLEEN FULLER EIC 1700 REMSEN 4B28 571/272-2505

L30 3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (AMMONIUM OR ?PYRIDIN? OR QAC)  
 L33 1 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) 40  
 L34 4 SEA FILE=HCAPLUS ABB=ON L30 OR L33  
 L35 0 SEA FILE=HCAPLUS ABB=ON L28 AND 40 (4A) (AMMONIUM OR ?PYRIDIN? OR QAC)  
 L36 3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
 L37 6 SEA FILE=HCAPLUS ABB=ON (L33 OR L34 OR L35 OR L36)  
 L39 20665 SEA FILE=WPIX ABB=ON PROPYLENE GLYCOL# OR PROPANEDIOL  
 L40 825 SEA FILE=WPIX ABB=ON CETYL(W)PYRIDINIUM(W)CHLORIDE OR CETYLPYRIDINIUM CHLORIDE OR CPC  
 L41 57 SEA FILE=WPIX ABB=ON L39 AND L40  
 L45 583 SEA FILE=WPIX ABB=ON CETYL(W)PYRIDINIUM(W)CHLORIDE OR CETYLPYRIDINIUM CHLORIDE  
 L46 27 SEA FILE=WPIX ABB=ON L45 AND (WEIGHT? OR WT) (4A) (40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
 L49 0 SEA FILE=BIOSIS ABB=ON L30 OR L37  
 L50 0 SEA FILE=BIOSIS ABB=ON L39 AND L46  
 L52 0 SEA FILE=MEDLINE ABB=ON L49 OR L50  
 L53 0 SEA FILE=MEDLINE ABB=ON L41 AND (WT OR WEIGHT?)  
 L54 0 SEA FILE=MEDLINE ABB=ON L28 AND (WEIGHT? OR WT)  
 L68 0 SEA FILE=JAPIO ABB=ON (L52 OR L53 OR L54)  
 L69 0 SEA FILE=JAPIO ABB=ON L39 AND L45  
 L70 0 SEA FILE=JAPIO ABB=ON L68 OR L69

=> file fsta

FILE 'FSTA' ENTERED AT 16:25:07 ON 26 MAR 2004

COPYRIGHT (C) 2004 International Food Information Service

FILE LAST UPDATED: 22 MAR 2004 <20040322/UP>

FILE COVERS 1969 TO DATE.

>>> THE NEW 2003 EDITION OF THE FSTA THESAURUS IS AVAILABLE NOW <<<

=> d que 172

L22 6 SEA FILE=REGISTRY ABB=ON (123-03-5/BI OR 56-81-5/BI OR 57-55-6/BI OR 16969-45-2/BI OR 25322-68-3/BI OR 64-17-5/BI)  
 L23 1 SEA FILE=REGISTRY ABB=ON L22 AND 1/CL  
 L24 1 SEA FILE=REGISTRY ABB=ON "PROPYLENE GLYCOL"/CN  
 L26 4203 SEA FILE=HCAPLUS ABB=ON L23  
 L27 21616 SEA FILE=HCAPLUS ABB=ON L24  
 L28 120 SEA FILE=HCAPLUS ABB=ON L26 AND L27  
 L30 3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (AMMONIUM OR ?PYRIDIN? OR QAC)  
 L33 1 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) 40  
 L34 4 SEA FILE=HCAPLUS ABB=ON L30 OR L33  
 L35 0 SEA FILE=HCAPLUS ABB=ON L28 AND 40 (4A) (AMMONIUM OR ?PYRIDIN? OR QAC)  
 L36 3 SEA FILE=HCAPLUS ABB=ON L28 AND (WEIGHT? OR WT) (4A) (40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
 L37 6 SEA FILE=HCAPLUS ABB=ON (L33 OR L34 OR L35 OR L36)  
 L39 20665 SEA FILE=WPIX ABB=ON PROPYLENE GLYCOL# OR PROPANEDIOL  
 L40 825 SEA FILE=WPIX ABB=ON CETYL(W)PYRIDINIUM(W)CHLORIDE OR CETYLPYRIDINIUM CHLORIDE OR CPC  
 L41 57 SEA FILE=WPIX ABB=ON L39 AND L40  
 L45 583 SEA FILE=WPIX ABB=ON CETYL(W)PYRIDINIUM(W)CHLORIDE OR

CETYLPYRIDINIUM CHLORIDE

L46 27 SEA FILE=WPIX ABB=ON L45 AND (WEIGHT? OR WT) (4A) (40 OR 41 OR  
42 OR 43 OR 44 OR 45 OR 39 OR 38 OR 37 OR 36)  
L49 0 SEA FILE=BIOSIS ABB=ON L30 OR L37  
L50 0 SEA FILE=BIOSIS ABB=ON L39 AND L46  
L52 0 SEA FILE=MEDLINE ABB=ON L49 OR L50  
L53 0 SEA FILE=MEDLINE ABB=ON L41 AND (WT OR WEIGHT?)  
L54 0 SEA FILE=MEDLINE ABB=ON L28 AND (WEIGHT? OR WT)  
L68 0 SEA FILE=JAPIO ABB=ON (L52 OR L53 OR L54)  
L69 0 SEA FILE=JAPIO ABB=ON L39 AND L45  
L72 0 SEA FILE=FSTA ABB=ON L68 OR L69

=> dup rem 138 148 167

FILE 'HCAPLUS' ENTERED AT 16:25:28 ON 26 MAR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 16:25:28 ON 26 MAR 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 16:25:28 ON 26 MAR 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

PROCESSING COMPLETED FOR L38

PROCESSING COMPLETED FOR L48

PROCESSING COMPLETED FOR L67

L73 11 DUP REM L38 L48 L67 (0 DUPLICATES REMOVED)

=> d 173 all 1-11

L73 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:77329 HCAPLUS  
 DN 138:121890  
 ED Entered STN: 31 Jan 2003  
 TI Concentrated non-foaming solutions of antimicrobial quaternary ammonium compounds for food use  
 IN Compadre, Cesar; Breen, Philip; Salari, Hamid; Fifer, E. Kim; Lattin, Danny L.; Slavik, Michael; Li, Yambin; O'Brien, Timothy; Waldroup, Amy L.; Berg, Thomas F.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U. S. 6,039,992.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A01N025-00  
 NCL 424405000  
 CC 17-4 (Food and Feed Chemistry)  
 FAN.CNT 4

*Applicants*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003021818	A1	20030130	US 2000-494374	20000131
	US 5855940	A	19990105	US 1996-631578	19960412
	US 6039992	A	20000321	US 1997-840288	19970414
	WO 2001054502	A2	20010802	WO 2001-US2450	20010126
	WO 2001054502	A3	20020307		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR	2001007967	A	20021029	BR 2001-7967	20010126
EP	1261318	A2	20021204	EP 2001-908695	20010126
EP	1261318	B1	20030903		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP	2003520608	T2	20030708	JP 2001-555491	20010126
AT	248585	E	20030915	AT 2001-1908695	20010126
EG	22162	A	20020930	EG 2001-97	20010131
ZA	2002006044	A	20030806	ZA 2002-6044	20020729
NO	2002003622	A	20020930	NO 2002-3622	20020730
PRAI	US 1996-631578	A2	19960412		
	US 1997-840288	A2	19970414		
	US 2000-494374	A1	20000131		
	WO 2001-US2450	W	20010126		

AB An antimicrobial for food use is composed of concentrated quaternary ammonium compound (QAC) solution (>10% by weight) and at least one solubility enhancing agent, such as an alc. The diluted QAC solution is used to prevent microbial growth on the food products from a broad spectrum of foodborne microbial contamination. The food products are contacted with the dilute QAC for  $\geq 0.1$  s. Thus, 8000 ppm cetylpyridinium chloride in 5% glycerol was effective against Salmonella typhimurium on chicken skin. The foods that can be treated by this method are meat and meat products, seafood, vegetables, fruit, dairy products, pet foods and

snacks, and any other food that can be treated and still retain its appearance and texture. One of the treatment methods is spraying and misting the QAC solns. on the food products for an application time of  $\geq 0.1$  s to prevent broad-spectrum foodborne microbial contamination.

ST antimicrobial quaternary ammonium compd food; cetylpyridinium antimicrobial food chicken

IT Alcohols, biological studies  
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
 (aliphatic; concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT Quaternary ammonium compounds, biological studies  
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
 (alkylalicyclic; concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT Meat  
 (beef; concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT Meat  
 (chicken; concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT Aeromonas hydrophila  
 Antimicrobial agents  
 Arcobacter butzleri  
 Aspergillus flavus  
 Bacillus cereus  
 Broccoli  
 Campylobacter jejuni  
 Catfish  
 Dairy products  
 Escherichia coli  
 Fish  
 Fruit  
 Grape  
 Listeria monocytogenes  
 Penicillium chrysogenum  
 Salmonella typhimurium  
 Solubilizers  
 Staphylococcus aureus  
 Vegetable  
 (concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT Alcohols, biological studies  
 Glycols, biological studies  
 Polyoxyalkylenes, biological studies  
 Quaternary ammonium compounds, biological studies  
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
 (concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT Feed  
 (pet food; concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT Skin  
 (poultry; concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT Food



(snack; concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT Quaternary ammonium compounds, biological studies

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)

(tetraalkyl; concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT **123-03-5**, Cetylpyridinium chloride

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)

(Cecure; concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

IT 56-81-5, Glycerol, biological studies 56-81-5D, Glycerol, derivs.

**57-55-6**, Propylene glycol, biological studies 64-17-5, Ethyl alcohol, biological studies 16969-45-2D, Pyridinium, alkyl derivs. 25322-68-3, Polyethylene glycol

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)

(concentrated non-foaming solns. of antimicrobial quaternary ammonium compds. for food use)

L73 ANSWER 2 OF 11 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
AN 2003-615510 [58] WPIX  
DNC C2003-167804  
TI Mouthspray formulation for combating plaque, oral bacteria, gingivitis,  
and oral malodor, includes alcohol, and bacterial agent comprising  
**cetyl pyridinium chloride** and domiphen  
bromide.  
DC D21 E19  
IN MILLS, S; TASHJIAN, A  
PA (INPL) PLAYTEX PROD INC  
CYC 2  
PI US 6579513 B1 20030617 (200358)\* 4p A61K007-16  
CA 2415518 A1 20030703 (200358) EN A61K007-16  
ADT US 6579513 B1 US 2002-38544 20020103; CA 2415518 A1 CA 2003-2415518  
20030103  
PRAI US 2002-38544 20020103  
IC ICM A61K007-16  
ICS A61K007-22  
AB US 6579513 B UPAB: 20030910  
NOVELTY - A mouthspray formulation comprises an alcohol, and a bacterial  
agent comprising **cetyl pyridinium chloride**  
and domiphen bromide in a ratio of 5:1.  
USE - The formulation is used for combating plaque, oral bacteria,  
gingivitis, and oral malodor.  
ADVANTAGE - The invention can be reliably and inexpensively  
manufactured.  
Dwg.0/0  
FS CPI  
FA AB; DCN  
MC CPI: D08-A; D08-A05; D08-B08; D08-B08B; E07-D04A; E10-A22A

L73 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:429542 HCAPLUS  
 DN 137:11003  
 ED Entered STN: 07 Jun 2002  
 TI Chondroprotective/restorative compositions containing hyaluronic acid  
 IN Pierce, Scott W.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 14 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-715  
 ICS A61K031-70  
 NCL 514054000  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1, 17

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002068718	A1	20020606	US 2001-967977	20011002
PRAI	US 2000-237838P	P	20001003		

AB An oral composition based on hyaluronic acid or its salts and optionally a therapeutic drug is provided for treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post-operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, and the reduction or inhibition of the production of hyaluronic acid in a mammal.

Addnl., compns. containing hyaluronic acid, chondroitin sulfate and glucosamine sulfate in a paste formulation are also described which can be administered on their own or can be used as a feed additive for cats and dogs. For example, a composition contained (by weight) glucosamine sulfate 36%, chondroitin sulfate 4%, sodium hyaluronate 0.144%, manganese sulfate 0.144%, ibuprofen 200 mg, powdered sugar 20%, glycerin 0.7%, xanthan gum 0.2%, sodium benzoate 0.7%, citric acid 0.2%, molasses 23.5%, and water 14.4%.

ST oral hyaluronic acid chondrocyte cartilage joint disorder; antiarthritic oral hyaluronic acid chondrocyte cartilage

IT Balsams

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Peru; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Natural products, pharmaceutical

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (aloe; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Caseins, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (calcium complexes; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Drug delivery systems

(capsules; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Natural products, pharmaceutical

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (cascara sagrada; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Analgesics  
Anti-inflammatory agents  
Antiarthritics  
Cat (Felis catus)  
Dog (Canis familiaris)  
Feed additives  
Horse (Equus caballus)  
Mammalia  
Molasses  
Nutrients  
Witch hazel  
(chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Amino acids, biological studies  
Castor oil  
Cocoa butter  
Cod liver oil  
Hydrocarbon oils  
Kaolin, biological studies  
Lanolin  
Lecithins  
Mineral elements, biological studies  
Sulfonamides  
Vitamins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Cartilage  
(degradation of; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Joint, anatomical  
(disease, effusion; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Leg  
(disease, lameness; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Drug delivery systems  
(gels; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Natural products, pharmaceutical  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ipecac; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Drug delivery systems  
(oral; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Drug delivery systems  
(pastes; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Essential oils  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(peppermint; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Fatty acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyunsatd., n-3; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Surgery

(post-operative arthroscopic surgery; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT Chondrocyte  
(reduction or inhibition of metabolic activity of;  
chondroprotective/restorative compns. containing hyaluronic acid for  
treatment of joint disorders)

IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sesame; chondroprotective/restorative compns. containing hyaluronic acid  
for treatment of joint disorders)

IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(shark-liver oil; chondroprotective/restorative compns. containing  
hyaluronic acid for treatment of joint disorders)

IT Synovial membrane, disease  
(synovitis; chondroprotective/restorative compns. containing hyaluronic  
acid for treatment of joint disorders)

IT 9004-61-9, Hyaluronic acid 9007-28-7, Chondroitin sulfate 9067-32-7,  
Sodium hyaluronate 29031-19-4, Glucosamine sulfate  
RL: FFD (Food or feed use); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(chondroprotective/restorative compns. containing hyaluronic acid for  
treatment of joint disorders)

IT 50-02-2 50-03-3, Hydrocortisone acetate 50-06-6, Phenobarbital,  
biological studies 50-13-5, Meperidine hydrochloride 50-21-5, Lactic  
acid, biological studies 50-23-7, Hydrocortisone 50-24-8, Prednisolone  
50-33-9, Phenylbutazone, biological studies 50-78-2, Acetylsalicylic  
acid 50-78-2D, Acetylsalicylic acid, buffered 50-81-7, L-Ascorbic  
acid, biological studies 51-42-3, Epinephrine bitartrate 51-98-9,  
Norethindrone acetate 52-28-8, Codeine phosphate 53-03-2, Prednisone  
53-86-1, Indomethacin 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0,  
Nitroglycerin 56-75-7, Chloramphenicol 56-81-5, Glycerin, biological  
studies 57-11-4, Stearic acid, biological studies 57-27-2, Morphine,  
biological studies 57-33-0, Pentobarbital sodium 57-41-0, Phenytoin  
57-55-6, Propylene glycol, biological studies 57-63-6, Ethinyl  
estradiol 58-08-2, Caffeine, biological studies 58-55-9, Theophylline,  
biological studies 58-85-5, Biotin 58-93-5, Hydrochlorothiazide  
59-30-3, Folic acid, biological studies 59-43-8, Thiamine, biological  
studies 59-67-6, Niacin, biological studies 61-33-6, biological  
studies 61-68-7, Mefenamic acid 61-76-7, Phenylephrine hydrochloride  
62-49-7, Choline 64-17-5, Ethanol, biological studies 64-19-7, Acetic  
acid, biological studies 64-75-5, Tetracycline hydrochloride 65-23-6,  
Pyridoxine 65-85-0, Benzoic acid, biological studies 67-63-0,  
Isopropanol, biological studies 67-68-5, Dimethyl sulfoxide, biological  
studies 67-71-0, Methylsulfonylmethane 68-04-2, Sodium citrate  
68-19-9, Cyanocobalamin 68-22-4, Norethindrone 69-53-4, Ampicillin  
69-72-7, Salicylic acid, biological studies 71-58-9, Medroxyprogesterone  
acetate 73-78-9, Lidocaine hydrochloride 76-22-2, Camphor 76-49-3,  
Bornyl acetate 76-57-3, Codeine 77-09-8, Phenolphthalein 77-41-8,  
Methsuximide 77-92-9, Citric acid, biological studies 78-11-5,  
Pentaerythritol tetranitrate 79-83-4 83-88-5, Riboflavin, biological  
studies 85-79-0, Dibucaine 87-67-2, Choline bitartrate, biological  
studies 87-89-8, myo-Inositol 88-04-0, Chloroxylonol 89-78-1,  
Menthol 90-64-2 93-14-1, Guaifenesin 93-60-7, Methyl nicotinate  
94-09-7, Benzocaine 94-36-0, Benzoyl peroxide, biological studies  
97-59-6, Allantoin 98-92-0, Niacinamide 100-97-0, Methenamine,  
biological studies 103-90-2, Acetaminophen 104-46-1, Anethole  
108-46-3, Resorcinol, biological studies 108-95-2, Phenol, biological

studies 112-38-9, Undecylenic acid 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 115-67-3, Paramethadione 117-10-2, Danthron 119-36-8, Methyl salicylate 119-61-9D, Benzophenone, derivs. **123-03-5**, Cetylpyridinium chloride 124-94-7, Triamcinolone 125-69-9, Dextromethorphan hydrobromide 126-07-8, Griseofulvin 128-49-4, Docusate calcium 131-53-3, Dioxybenzone 131-57-7, Oxybenzone 132-20-7, Pheniramine maleate 134-31-6, 8-Hydroxyquinoline sulfate 136-77-6, Hexylresorcinol 137-58-6, Lidocaine 139-12-8, Aluminum acetate 140-65-8, Pramoxine 141-01-5, Ferrous fumarate 143-71-5, Hydrocodone bitartrate 144-55-8, Sodium bicarbonate, biological studies 147-24-0, Diphenhydramine hydrochloride 150-13-0, p-Aminobenzoic acid 152-11-4, Verapamil hydrochloride 152-43-2, Quinestrol 154-41-6, Phenylpropanolamine hydrochloride 156-51-4, Phenelzine sulfate 299-29-6, Ferrous gluconate 299-42-3, Ephedrine 302-79-4, Tretinoin 303-25-3, Cyclizine hydrochloride 318-98-9, Propranolol hydrochloride 321-64-2, Tacrine 345-78-8, Pseudoephedrine hydrochloride 395-28-8 439-14-5, Diazepam 443-48-1, Metronidazole 469-62-5, Propoxyphene 470-82-6, Eucalyptol 471-34-1, Calcium carbonate, biological studies 532-03-6, Methocarbamol 532-32-1, Sodium benzoate 546-93-0, Magnesium carbonate 550-70-9, Triprolidine hydrochloride 557-04-0, Magnesium stearate 557-08-4, Zinc undecylenate 562-10-7 577-11-7, Docusate sodium 603-50-9, Bisacodyl 614-39-1, Procainamide hydrochloride 637-07-0, Clofibrate 637-58-1, Pramoxine hydrochloride 644-62-2, Meclofenamic acid 723-46-6, Sulfamethoxazole 980-71-2, Brompheniramine maleate 1218-35-5, Xylometazoline hydrochloride 1305-62-0, Calcium hydroxide, biological studies 1309-42-8, Magnesium hydroxide 1321-11-5, Aminobenzoic acid 1327-41-9, Aluminum chlorohydrate 1400-61-9, Nystatin 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin B sulfate 1405-41-0, Gentamycin sulfate 1405-87-4, Bacitracin 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1639-60-7, Propoxyphene hydrochloride 1684-40-8, Tacrine hydrochloride 2391-03-9, Dexbrompheniramine maleate 2398-96-1, Tolnaftate 2955-38-6, Prazepam 3380-34-5, Triclosan 4205-90-7, Clonidine 4205-91-8, Clonidine hydrochloride 4499-40-5, Oxtriphylline, biological studies 5466-77-3, Octyl methoxycinnamate 5534-09-8, Beclomethasone dipropionate 5874-97-5, Metaproterenol sulfate 6385-02-0, Meclofenamate sodium 6740-88-1, Ketamine 7054-25-3, Quinidine gluconate 7280-37-7, Estropipate 7439-89-6, Iron, biological studies 7439-96-5, Manganese, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 7447-40-7, Potassium chloride, biological studies 7460-12-0, Pseudoephedrine sulfate 7491-09-0, Docusate potassium 7553-56-2, Iodine, biological studies 7631-86-9, Silicon dioxide, biological studies 7647-14-5, Sodium chloride (NaCl), biological studies 7681-49-4, Sodium fluoride, biological studies 7704-34-9, Sulfur, biological studies 7720-78-7, Ferrous sulfate 7723-14-0, Phosphorus, biological studies 7733-02-0, Zinc sulfate 7757-79-1, Potassium nitrate, biological studies 7785-87-7, Manganese sulfate 8011-96-9, Calamine 8025-63-6 8050-81-5, Simethicone 8065-29-0, Liotrix 9004-10-8, Insulin, biological studies 9004-32-4, Sodium carboxymethyl cellulose 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies 9006-65-9, Dimethicone 9036-19-5, Octoxynol 10163-15-2, Sodium monofluorophosphate 11041-12-6, Cholestyramine resin 11096-26-7, Erythropoietin 11099-07-3, Glyceryl stearate 11103-57-4, Vitamin A 11111-12-9D, Cephalosporin, derivs. 11138-66-2, Xanthan gum 12001-76-2, Vitamin B 12001-79-5, Vitamin K 14362-31-3, Chlorcyclizine hydrochloride 14455-29-9, Aluminum carbonate 14663-23-1, Dantrium 14698-29-4, Oxolinic acid 14838-15-4, Phenylpropanolamine 14987-04-3,

Magnesium trisilicate 15307-79-6, Diclofenac sodium 15686-71-2, Cephalexin 15687-27-1, Ibuprofen 17140-78-2, Propoxyphene napsylate 18472-51-0, Chlorhexidine gluconate 18559-94-9, Albuterol 18917-89-0, Magnesium salicylate 20830-75-5, Digoxin 21245-02-3, Padimate O 21645-51-2, Aluminum hydroxide, biological studies 21829-25-4, Nifedipine 22204-53-1, Naproxen 22832-87-7, Miconazole nitrate 22839-47-0, Aspartame 24390-14-5, Doxycycline hyclate 25441-16-1 25812-30-0, Gemfibrozil 26027-38-3, Nonoxynol-9 26159-34-2, Naproxen sodium 26171-23-3, Tolmetin 26787-78-0, Amoxicillin 26921-17-5, Timolol maleate 28911-01-5, Triazolam 28981-97-7, Alproazolam 29094-61-9, Glipizide 29122-68-7, Atenolol 29984-33-6, Vidarabine phosphate 34552-84-6, Isoxicam 34580-13-7, Ketotifen  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT 36322-90-4, Piroxicam 36505-84-7, Buspirone 36653-82-4, Cetyl alcohol 37148-27-9, Clenbuterol 38304-91-5, Minoxidil 42399-41-7, Diltiazem 42461-84-7, Flunixin Meglumine 50370-12-2, Cefadroxil 50679-08-8, Terfenadine 51022-70-9, Albuterol sulfate 51264-14-3, Amsacrine 52128-35-5, Trimetrexate 52618-67-4, Tioperidone 53910-25-1, Pentostatin 53994-73-3, Cefaclor 56296-78-7, Fluoxetine hydrochloride 56392-17-7, Metoprolol tartrate 59729-33-8, Citalopram 60142-96-3, Gabapentin 62571-86-2, Captopril 66357-35-5, Ranitidine 68252-19-7, Pirmenol 68497-62-1, Pramiracetam 69198-10-3, Metronidazole hydrochloride 70059-30-2, Cimetidine hydrochloride 72332-33-3, Procaterol 73590-58-6, Omeprazole 74011-58-8, Enoxacin 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 80841-47-0, Amsalog 85441-61-8, Quinapril 88637-37-0, Diphenhydramine citrate 89197-32-0, Efaroxan 93107-08-5, Ciprofloxacin hydrochloride 93390-81-9, Fosphenytoin 93738-40-0, Ralitoline 96328-17-5, 2'-Chloropentostatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

IT 9004-34-6, Cellulose, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

L73 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:564783 HCAPLUS  
 DN 135:136676  
 ED Entered STN: 03 Aug 2001  
 TI Concentrated, nonfoaming solution of quaternary ammonium compounds as food microbicide  
 IN Compadre, Cesar; Breen, Philip; Salari, Hamid; Fifer, E. Kim; Lattin, Danny L.; Slavik, Michael; Li, Yanbin; O'Brien, Timothy; Waldroup, Amy L.; Berg, Thomas F.  
 PA University of Arkansas, USA  
 SO PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A01N043-40  
 ICS A01N033-12; A23L003-3526; A01N043-40; A01N031-02; A01N025-30; A01N025-02; A01N033-12; A01N031-02; A01N025-30; A01N025-02  
 CC 17-4 (Food and Feed Chemistry)  
 Section cross-reference(s): 10

*applicant*

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001054502	A2	20010802	WO 2001-US2450	20010126
	WO 2001054502	A3	20020307		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2003021818	A1	20030130	US 2000-494374	20000131
	BR 2001007967	A	20021029	BR 2001-7967	20010126
	EP 1261318	A2	20021204	EP 2001-908695	20010126
	EP 1261318	B1	20030903		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003520608	T2	20030708	JP 2001-555491	20010126
	AT 248585	E	20030915	AT 2001-1908695	20010126
	NO 2002003622	A	20020930	NO 2002-3622	20020730
PRAI	US 2000-494374	A1	20000131		
	US 1996-631578	A2	19960412		
	US 1997-840288	A2	19970414		
	WO 2001-US2450	W	20010126		
AB	A concentrated quaternary ammonium compound (QAC) solution comprising a QAC at $\geq 10$ by <b>weight</b> and at least one solubility-enhancing agent, such as an alc., is disclosed. A diluted QAC solution is used to contact food products to prevent microbial growth from a broad-spectrum of food-borne microbial contaminants. A method of contacting the food products with the dilute QAC for an application time of $\geq 0.1$ s is disclosed. The foods that can be treated by this method are meat and meat products, seafood, vegetables, fruit, dairy products, pet foods and snacks, and any other food that can be treated and still retain its appearance and texture. One of the treatment methods is spraying and misting the QAC solns. on the food products.				
ST	quaternary ammonium compd soln food microbicide				



IT Quaternary ammonium compounds, biological studies  
RL: BUU (Biological use, unclassified); FFD (Food or feed use); BIOL  
(Biological study); USES (Uses)  
(quaternary ammonium compound solution as food microbicide)

IT Antibacterial agents  
Food preservatives  
(quaternary ammonium compds. as food microbicide)

IT Alcohols, uses  
Glycols, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(solubilizers for concentrated solution of quaternary ammonium compds. as  
food  
microbicide)

IT **123-03-5**, Cetylpyridinium chloride  
RL: BUU (Biological use, unclassified); FFD (Food or feed use); BIOL  
(Biological study); USES (Uses)  
(quaternary ammonium compound solution as food microbicide)

IT **57-55-6**, propylene glycol, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(solubilizer for concentrated solution of quaternary ammonium compds. as  
food  
microbicide)

L73 ANSWER 5 OF 11 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 2001-496563 [54] WPIX

CR 1999-460548 [39]

DNC C2001-149069

TI Antimicrobial composition useful for disinfecting e.g., skin, comprises alcohol, cationic quaternary ammonium compound, phenoxy ethanol, and surfactant system excluding anionic surfactant.

DC A96 D21 D22 E19

IN HOLLY, T F; JAMPANI, H; NEWMAN, A W; NEWMAN, J L; JAMPANI, H B

PA (ETHI) ETHICON INC; (JAMP-I) JAMPANI H B; (NEWM-I) NEWMAN A W; (NEWM-I) NEWMAN J L

CYC 95

PI WO 2001041567 A1 20010614 (200154)\* EN 50p A01N031-02

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM  
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC  
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE  
SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2001029074 A 20010618 (200161) A01N031-02

EP 1161146 A1 20011212 (200204) EN A01N031-02

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL RO  
SI

US 2002022660 A1 20020221 (200221) A61K031-155

JP 2003515612 W 20030507 (200331) 77p A61K031-155

ADT WO 2001041567 A1 WO 2000-US33689 20001213; AU 2001029074 A AU 2001-29074  
20001213; EP 1161146 A1 EP 2000-993301 20001213; WO 2000-US33689 20001213;  
US 2002022660 A1 CIP of US 1998-9596 19980120, US 1999-460014 19991213; JP  
2003515612 W WO 2000-US33689 20001213, JP 2001-542752 20001213

FDT AU 2001029074 A Based on WO 2001041567; EP 1161146 A1 Based on WO  
2001041567; US 2002022660 A1 CIP of US 6022551; JP 2003515612 W Based on  
WO 2001041567

PRAI US 1999-460014 19991213; US 1998-9596 19980120

IC ICM A01N031-02; A61K031-155

ICS A01N025-30; A01N031-14; A01N033-12; A01N033-14; A01N047-44;  
A61K006-00; A61K007-00; A61K031-085; A61K031-14; A61K031-45;  
A61K047-10; A61K047-14; A61K047-20; A61P017-00; A61P031-04

ICI A01N031:14; A01N031-02, A01N033:12, A01N047:44; A01N047:44; A01N033:12;  
A01N031:14; A01N031-02

AB WO 200141567 A UPAB: 20030516

NOVELTY - An antimicrobial composition comprises an alcohol, a cationic quaternary ammonium compound, phenoxy ethanol, optionally biguanide compound, and surfactant system excluding anionic surfactant.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method of disinfecting a substrate by applying the inventive antimicrobial composition.

USE - For disinfecting substrates e.g., skin, hands, acne sites, patient prepping sites, or injection site for catheters.

ADVANTAGE - The inventive composition provides instant and long-lasting antimicrobial activity.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: A05-J; A06-A00E3; A10-E01; A12-V01; A12-V04; A12-V04C; D08-B09A;  
D08-B13; D09-A01; D09-C04; E07-A02A; E07-A02D; E07-A02H; E07-D04A;  
E10-A09B8; E10-A17B; E10-A21; E10-A22; E10-E04G; E10-E04L; E10-E04M1

L73 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:119731 HCAPLUS  
 DN 130:200749  
 ED Entered STN: 23 Feb 1999  
 TI Cosmetic compositions with DBS and functionalized silicones  
 IN Gutierrez, Adriana Urrutia; Albanese, Joseph James; Bianchini, Robert  
 Joseph; Fantano, Steven Louis  
 PA Colgate-Palmolive Company, USA  
 SO U.S., 14 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM A61K007-00  
 NCL 424065000  
 CC 62-4 (Essential Oils and Cosmetics)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5871720	A	19990216	US 1997-974946	19971120
	CA 2310791	AA	19990603	CA 1998-2310791	19981119
	WO 9926603	A1	19990603	WO 1998-US24660	19981119
	W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 9915293	A1	19990615	AU 1999-15293	19981119
	AU 743749	B2	20020207		
	ZA 9810596	A	20000519	ZA 1998-10596	19981119
	EP 1035830	A1	20000920	EP 1998-959506	19981119
	EP 1035830	B1	20020227		
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, LT, LV, FI, RO		
	BR 9814229	A	20001003	BR 1998-14229	19981119
	JP 2001523703	T2	20011127	JP 2000-521805	19981119
	AT 213622	E	20020315	AT 1998-959506	19981119
	PT 1035830	T	20020830	PT 1998-98959506	19981119
	ES 2174517	T3	20021101	ES 1998-959506	19981119
	NZ 504653	A	20021220	NZ 1998-504653	19981119
	RU 2214225	C2	20031020	RU 2000-115583	19981119
	NO 2000002576	A	20000719	NO 2000-2576	20000519
	BG 104538	A	20010131	BG 2000-104538	20000615
PRAI	US 1997-974946	A	19971120		
	WO 1998-US24660	W	19981119		

AB The invention comprises a cosmetic composition which is a translucent to clear stick having low tack. The cosmetic sticks are formed by combining (a) from 5.0-50.0 weight percent of a silicone fluid phase which comprises at least one hydroxy functionalized silicone fluid, at least one stabilizing agent and, optionally at least one addnl. silicone material; (b) from 40-95 weight percent of a gellant/solvent phase which comprises a mixture of dibenzylidene sorbitol (DBS) and at least one solvent such as a polyhydric alc. (for example, propylene glycol); and (c) an effective amount of at least one active ingredient. A composition was prepared containing silanol 25.0, Surfactant DC3225C 3.0, DC 556 Fluid 5.0, propylene glycol 34.5, DBS 2.0, hydroxypropyl cellulose 0.5, and Al Zr

tetrachlorohydrate-Gly 30.0.

ST cosmetic dibenzylidene sorbitol silicone

IT Surfactants  
(cosmetic compns. with dibenzylidene sorbitol and functionalized silicones)

IT Polysiloxanes, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(cosmetic compns. with dibenzylidene sorbitol and functionalized silicones)

IT Paraffin oils  
Polyoxyalkylenes, biological studies  
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)  
(cosmetic compns. with dibenzylidene sorbitol and functionalized silicones)

IT Polysiloxanes, biological studies  
Polysiloxanes, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(polyether-; cosmetic compns. with dibenzylidene sorbitol and functionalized silicones)

IT Alcohols, biological studies  
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)  
(polyhydric; cosmetic compns. with dibenzylidene sorbitol and functionalized silicones)

IT Polyethers, biological studies  
Polyethers, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(siloxane-; cosmetic compns. with dibenzylidene sorbitol and functionalized silicones)

IT 9016-00-6, Polydimethylsiloxane 28323-47-9, Poly[oxy(diethylsilylene)] 28576-55-8, Poly[oxy(ethylmethylsilylene)] 31900-57-9, Polydimethylsiloxane 32647-67-9, Dibenzylidene sorbitol 56267-41-5, Silanediol, diethyl-, homopolymer 155940-31-1, Polyethylmethylsiloxane  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(cosmetic compns. with dibenzylidene sorbitol and functionalized silicones)

IT 50-70-4, Sorbitol, biological studies 56-81-5, 1,2,3-Propanetriol, biological studies 57-09-0, Cetyltrimethylammonium bromide 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, 1,2-Propanediol, aluminum complexes, biological studies 64-17-5, Ethanol, biological studies 101-20-2 107-88-0, 1,3-Butanediol 108-32-7, Propylene carbonate 110-27-0, Isopropyl myristate 110-63-4, 1,4-Butanediol, biological studies 118-60-5, Octyl salicylate 123-03-5, Cetylpyridinium chloride 124-68-5, 2-Amino-2-methyl-1-propanol 131-57-7, Oxybenzone 134-62-3, N,N-Diethyl-m-toluamide 142-91-6, Isopropyl palmitate 143-28-2 150-13-0, p-Aminobenzoic acid 872-50-4, N-Methylpyrrolidone, biological studies 1327-41-9, Aluminum chlorhydroxide 3380-34-5, 2,4,4'-Trichloro-2'-hydroxydiphenyl ether 5466-77-3 7429-90-5D, Aluminum, complexes with propylene glycol, biological studies 7446-70-0, Aluminum chloride, biological studies 7491-02-3, Diisopropyl sebacate 11078-30-1D, D-Galacto-D-mannan, alkyl ethers 13040-19-2, Zinc ricinoleate 18428-88-1, Zirconyl hydroxychloride 24800-44-0,

Tripropylene glycol 25265-71-8, Dipropylene glycol 25322-68-3  
 25322-69-4, Polypropylene glycol 25657-08-3, Tetrapropylene glycol  
 52227-36-8, Aluminum sesquichloride 100224-74-6, Guanidine carbonate  
 125913-22-6, Aluminum zirconium pentachlorohydrex-Gly 134375-99-8,  
 Aluminum zirconium trichlorohydrex-Gly 134910-86-4, Aluminum zirconium  
 tetrachlorohydrex-Gly 173720-80-4, Aluminum dichlorohydrex PEG  
 173762-81-7, Aluminum chlorohydrex PEG 173762-82-8, Aluminum  
 chlorohydrex PG 174514-58-0, Aluminum zirconium octachlorohydrex-Gly  
 180324-83-8, Aluminum dichlorohydrex PG  
 RL: BUU (Biological use, unclassified); MOA (Modifier or additive use);  
 BIOL (Biological study); USES (Uses)  
 (cosmetic compns. with dibenzylidene sorbitol and functionalized  
 silicones)

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Anon; EP 0260030 A2 1988 HCAPLUS
- (2) Anon; EP 0291334 A2 1988 HCAPLUS
- (3) Anon; EP 0451002 A2 1991 HCAPLUS
- (4) Anon; EP 0512770 A1 1992 HCAPLUS
- (5) Anon; WO 9219221 1992 HCAPLUS
- (6) Anon; GB 2280111 A 1994 HCAPLUS
- (7) Anon; WO 9626709 1996 HCAPLUS
- (8) Beck; US 4863721 1989 HCAPLUS
- (9) Kasat; US 5490979 1996 HCAPLUS
- (10) Kasprzak; US 5302382 1994 HCAPLUS
- (11) Lengnick; US 3441537 1969 HCAPLUS
- (12) Luebbe; US 4816261 1989 HCAPLUS
- (13) Marscher; US 4440742 1984 HCAPLUS
- (14) Oh; US 5609855 1997 HCAPLUS
- (15) Randhawa; US 4719102 1988 HCAPLUS
- (16) Ross; US 5500209 1996 HCAPLUS
- (17) Ross; US 5603925 1997 HCAPLUS
- (18) Sabatelli; US 4822602 1989 HCAPLUS
- (19) Schamper; US 4518582 1985 HCAPLUS
- (20) Schamper; US 4720381 1988 HCAPLUS
- (21) Schamper; US 4722835 1988 HCAPLUS
- (22) Schamper; US 4725430 1988 HCAPLUS
- (23) Schweiss; US 4346097 1982 HCAPLUS
- (24) Shevade; US 5531986 1996 HCAPLUS
- (25) Shin; US 5405605 1995 HCAPLUS
- (26) Walter, N; Chemistry and Technology of Silicones 1968, P190
- (27) Wolf; US 5449519 1995 HCAPLUS
- (28) Zombeck, A; Novel Formulations Bawsed on Nonaqueous Emulsions of Polyols  
 in Silciones 1996, V22, P1

L73 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:375248 HCAPLUS  
 DN 131:23276  
 ED Entered STN: 17 Jun 1999  
 TI Oral composition for the treatment of halitosis containing chlorhexidine  
 and quaternary ammonium salts  
 IN Masdevall Noguera, Enrique  
 PA Dentaaid, S.A., Spain  
 SO Eur. Pat. Appl., 7 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 IC ICM A61K007-16  
 ICS A61K007-22  
 CC 62-7 (Essential Oils and Cosmetics)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 920857	A2	19990609	EP 1998-500189	19980810
	EP 920857	A3	20030102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	ES 2132033	A1	19990801	ES 1997-2305	19971106
	ES 2132033	B1	20000301		
PRAI	ES 1997-2305	A	19971106		

AB An oral composition contain (a) chlorhexidine digluconate in a concentration by weight of 0.025 to 0.20% or other soluble and pharmaceutically acceptable chlorhexidine salt in an equivalent concentration of chlorhexidine base; (b) cetyl pyridinium chloride or other pharmaceutically acceptable salt of quaternary ammonium in a concentration by weight of 0.025 to 0.10%; (c) a pharmaceutically acceptable salt or compound of Zn+2 and/or Cu+2 which includes from 100 to 1,000 ppm of Zn+2 and/or Cu+2 ions. The present invention also relates to the use of said composition for obtaining a mouth rinse, a dental paste, a dental powder or dental chewing gum for the treatment of oral halitosis. An oral composition contained chlorhexidine digluconate 0.05, cetyl pyridinium chloride 0.05, zinc gluconate 0.50, saccharine 0.01, xylitol 5.0, glycerin 5.0, dyes 0.0001, ethoxylated and hydrogenated castor oil 0.60, essence 0.15, 96% alc. 5.0, and water q.s., 100%. pH = 6.30. Antimicrobial activity of the active ingredient of the above composition was studied.

ST oral halitosis chlorhexidine quaternary ammonium salt

IT Betaines  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(amido; oral composition for treatment of halitosis containing chlorhexidine and quaternary ammonium salts)

IT Surfactants  
 (amphoteric; oral composition for treatment of halitosis containing chlorhexidine and quaternary ammonium salts)

IT Castor oil  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (ethoxylated; oral composition for treatment of halitosis containing chlorhexidine and quaternary ammonium salts)

IT Mouth  
 (halitosis; oral composition for treatment of halitosis containing chlorhexidine

and quaternary ammonium salts)

IT Castor oil  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (hydrogenated, ethoxylated; oral composition for treatment of halitosis  
 containing chlorhexidine and quaternary ammonium salts)

IT Surfactants  
 (nonionic; oral composition for treatment of halitosis containing  
 chlorhexidine  
 and quaternary ammonium salts)

IT Dyes  
 Mouthwashes  
 Wetting agents  
 (oral composition for treatment of halitosis containing chlorhexidine and  
 quaternary ammonium salts)

IT Polyoxyalkylenes, biological studies  
 Quaternary ammonium compounds, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (oral composition for treatment of halitosis containing chlorhexidine and  
 quaternary ammonium salts)

IT 50-70-4, Sorbitol, biological studies 56-81-5, 1,2,3-Propanetriol,  
 biological studies **57-55-6**, 1,2-Propanediol, biological studies  
 81-07-2, Saccharine 87-99-0, Xylitol **123-03-5**, Cetyl  
 pyridinium chloride 124-30-1D, Octadecylamine, fluorinated derivs.  
 527-09-3, Copper gluconate 1338-39-2, Sorbitan monolaurate 3151-59-5  
 4180-12-5, Copper acetate 4468-02-4, Zinc gluconate 7646-85-7, Zinc  
 chloride, biological studies 7681-49-4, Sodium fluoride, biological  
 studies 9003-11-6 16039-53-5, Zinc lactate 18472-51-0, Chlorhexidine  
 digluconate 25322-68-3 54392-26-6, Sorbitan monoisostearate  
 226418-81-1  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (oral composition for treatment of halitosis containing chlorhexidine and  
 quaternary ammonium salts)

L73 ANSWER 8 OF 11 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 2000-052807 [04] WPIX  
 CR 1999-060000 [05]; 1999-060030 [05]; 1999-060321 [05]; 1999-060322 [05];  
 1999-060323 [05]; 2000-038644 [03]; 2000-038645 [03]; 2000-601270 [57];  
 2003-644651 [61]  
 DNN N2000-041213 DNC C2000-013592  
 TI Improved uncomplexed cyclodextrin composition for odor and wrinkle control  
 in inanimate surfaces especially fabrics, curtains, drapes and carpets.  
 DC A26 A97 D22 D25 E19 F06 P34 P42  
 IN BOLICH, R E; BURNS, A J; CAMPBELL, W T; CHUNG, A H; COBB, D S;  
 MERMELSTEIN, R; PEFFLY, M M; ROSENBALM, E L; SCHNEIDERMAN, E; STREUTKER, A  
 D; TORDIL, H B; TRINH, T; WARD, T E; WOLFF, A M; WOO, R A  
 PA (PROC) PROCTER & GAMBLE CO  
 CYC 72  
 PI WO 9955814 A1 19991104 (200004)\* EN 84p C11D003-22  
 RW: EA GH GM KE LS MW OA SD SZ UG ZW  
 W: AL AM AT AU AZ BA BB BG BR BY CH CN CU CZ DE DK EE ES FI GB GE GH  
 GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK  
 MN MW NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN  
 YU ZW  
 ZA 9811265 A 20000126 (200011) 84p C08B000-00  
 AU 9918046 A 19991116 (200015)  
 BR 9815835 A 20001226 (200103) C11D003-22  
 AU 740341 B 20011101 (200175) C11D003-22  
 ADT WO 9955814 A1 WO 1998-US25796 19981208; ZA 9811265 A ZA 1998-11265  
 19981209; AU 9918046 A AU 1999-18046 19981208; BR 9815835 A BR 1998-15835  
 19981208; WO 1998-US25796 19981208; AU 740341 B AU 1999-18046 19981208  
 FDT AU 9918046 A Based on WO 9955814; BR 9815835 A Based on WO 9955814; AU  
 740341 B Previous Publ. AU 9918046, Based on WO 9955814  
 PRAI US 1998-67639 19980427; US 1998-67182 19980427; US 1998-67184  
 19980427; US 1998-67240 19980427; US 1998-67241 19980427; US  
 1998-67243 19980427; US 1998-67385 19980427; US 1998-67387  
 19980427  
 IC ICM C08B000-00; C11D003-22  
 ICS A61L009-01; B05C000-00; C08L000-00; C11D017-04; D06M013-00;  
 D06M015-03; D06M023-06  
 AB WO 9955814 A UPAB: 20030923  
 NOVELTY - A stable aqueous odor absorbing composition comprises a  
 solubilized uncomplexed cyclodextrin, cyclodextrin compatible fabric  
 wrinkle control agent and optionally a cyclodextrin compatible surfactant,  
 an antimicrobial active and preservative, perfume ingredients, low  
 molecular weight polyol, aminocarboxylate chelator, metallic salt, an  
 enzyme and an aqueous carrier.  
 DETAILED DESCRIPTION - A stable, aqueous odor-absorbing composition  
 comprises:  
 (A) a solubilized, uncomplexed cyclodextrin (A) to absorb malodors;  
 (B) optionally a cyclodextrin compatible surfactant (B) to improve  
 the composition performance;  
 (C) optionally a cyclodextrin compatible and water soluble  
 antimicrobial active (C) to kill or reduce the growth of microorganisms;  
 (D) optionally a hydrophilic perfume (D) containing 50 weight% (weight  
 %) or more of perfume ingredients having a ClogP of 3.5 or less and a  
 small amount of perfume ingredients selected from ambrox, bacdanol, benzyl  
 salicylate, butyl anthranilate, cetalox, damascenone, alpha - damascone,  
 gamma -dodecalactone, ebanol, herbavert, cis-3-hexenyl salicylate, alpha  
 -ionone, beta -ionone, alpha -isomethylionone, lillial, methyl nonyl  
 ketone, gamma -undecalactone, undecylenic aldehyde and their mixtures;  
 (E) optionally 0.01-3 weight % of low molecular weight polyol (E);



(F) optionally 0.001-0.3 weight % of aminocarboxylate chelator (F);  
 (G) optionally a metallic salt (G) to improve odor benefit;  
 (H) optionally an enzyme (H) to improve odor control benefit,  
 optionally a solubilized water soluble;  
 (I) antimicrobial preservative (I);  
 (J) a cyclodextrin compatible fabric wrinkle control agent (J)  
 optionally selected from cyclodextrin compatible shape retention polymer,  
 cyclodextrin compatible plasticizers, cyclodextrin compatible lithium  
 salts and their mixtures; and  
 (K) aqueous carrier (K).

The composition contains (B) and/or (C) and/or the composition is essentially free of any material that would soil or stain fabrics during usage and has a pH of 3.5 or more. The composition packed in a container is capable of dispensing small droplets having a weight average diameter of 10-120  $\mu$ m.

An INDEPENDENT CLAIM is also included for odor and wrinkle control method for fabrics, which involves spraying the cyclodextrin composition onto the surface using either a trigger spray device or a non manually operated sprayers such as powered sprayers, air aspirated sprayers, liquid aspirated sprayers, electrostatic sprayers or nebulizer sprayers, spraying droplets having a weight average diameter of 10-120  $\mu$ m.

USE - For inanimate surfaces especially fabrics and fibers such as cotton fabrics and fibers, clothes, curtain, drapes, upholstered furniture, carpeting, bed linens, bath linens, table cloths, sleeping bags, tents, car interiors etc. Also sprayed into major household appliances such as refrigerators, freezers, washing machines, automatic dryers, ovens, microwave ovens and dishwashers, cat litter, pet bedding and pet houses.

ADVANTAGE - The composition is stable, clear and aqueous and controls wrinkles and absorbs odor on fabrics. The composition controls odors caused by a broad spectrum of organic odoriferous materials of food odors, body odor, breath odor, urine, excretions and remains shelf stable for a substantial period of time. The odor absorbing compositions restore and/or maintain freshness of the fabric by reducing malodor without washing or dry cleaning. The composition minimizes the occurrence of fabric staining and improves fabric appearance by minimizing localized spottings. The composition spreads readily and uniformly on hydrophobic surfaces such as polyester and nylon. The composition dries faster allowing ready use of the treated material. The composition improves in-wear electrostatic control and antimicrobial performance. The composition releases the fiber from wrinkling in wet or damp fabric. The residual silicone in the composition reduces fabric rewrinkling after drying. The composition has adhesive and film forming properties. The composition promotes spreading of the solution and provides improved odor control and antimicrobial action. The composition applied in the form of very small particles, enhances the uniform distribution of the composition and improves the overall performance.

Dwg.0/0

FS CPI GMPI

FA AB; DCN

MC CPI: A03-A00A; A08-M02; A08-M04; A12-G; D09-A01C; D11-B14; D11-B15B;  
 D11-D; E05-A; E05-E; E06-A03; E10-C02F; E10-E04H; E10-E04J; E33-G;  
 F03-C; F03-C02B; F03-C04; F03-C05

L73 ANSWER 9 OF 11 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
 on STN  
 AN 97043559 EMBASE  
 DN 1997043559  
 TI Transdermal iontophoresis of sodium nonivamide acetate II: Optimization  
 and evaluation on solutions and gels.  
 AU Fang J.-Y.; Huang Y.-B.; Wu P.-C.; Tsai Y.-H.  
 CS Y.-H. Tsai, School of Pharmacy, Kaohsiung Medical College, Kaohsiung ROC,  
 Taiwan, Province of China  
 SO International Journal of Pharmaceutics, (1996) 145/1-2 (175-186).  
 Refs: 46  
 ISSN: 0378-5173 CODEN: IJPHDE  
 PUI S 0378-5173(96)04767-9  
 CY Netherlands  
 DT Journal; Article  
 FS 013 Dermatology and Venereology  
 030 Pharmacology  
 037 Drug Literature Index  
 039 Pharmacy  
 LA English  
 SL English  
 AB Sodium nonivamide acetate (SNA) is a newly designed derivative of  
 capsaicin which reveals marked antinociceptive activity without producing  
 an overt pungent sensation and skin irritation. The following  
 iontophoretic drug delivery issues have been examined in this paper: (1)  
 the competitive ion effect; (2) transdermal iontophoretic delivery from  
 gel base; and (3) maximization of iontophoretic application mode from gel  
 base. According to the theory of molal volume, divalent salt ions show  
 higher buffering capacity on SNA iontophoretic transport than did  
 monovalent salt ions. However, this effect also causes a great reduction  
 of SNA transdermal flux. The experimental result of transdermal  
 iontophoresis of gel indicated the flux of SNA decreased following the  
 increase of viscosity. Using various polymers incorporated in gel  
 formulations, indicated methyl cellulose and hydroxypropyl methyl  
 cellulose showed higher capacity for SNA iontophoretic transport than the  
 other materials. After a series of evaluation and optimization on the  
 iontophoretic delivery of SNA, transdermal iontophoresis has provided a  
 great capacity of enhancing SNA transport across the skin. The result of  
 the present study is particularly helpful in the development of SNA  
 transdermal delivery system and holds promise for the successful clinical  
 development of an antinociceptive therapeutic regimen.  
 CT Medical Descriptors:  
 \*drug transport  
 \*iontophoresis  
 \*skin penetration  
 animal tissue  
 article  
 controlled study  
 gel  
 ionic strength  
**molecular weight**  
 nonhuman  
 priority journal  
 rat  
 solution and solubility  
 viscosity  
 Drug Descriptors:  
**\*capsaicin derivative: CB, drug combination**

\*capsaicin derivative: PR, pharmaceuticals  
 \*capsaicin derivative: PK, pharmacokinetics  
 \*capsaicin derivative: AN, drug analysis  
 \*sodium nonivamide acetate: PK, pharmacokinetics  
 \*sodium nonivamide acetate: PR, pharmaceuticals  
 \*sodium nonivamide acetate: CB, drug combination  
 \*sodium nonivamide acetate: AN, drug analysis  
 anion  
 benzalkonium: CM, drug comparison  
 benzalkonium: CB, drug combination  
 carbopol 940: CM, drug comparison  
 carbopol 940: CB, drug combination  
 carboxymethylcellulose: CM, drug comparison  
 carboxymethylcellulose: CB, drug combination  
 cetrimide: CM, drug comparison  
 cetrimide: CB, drug combination  
 cetylpyridinium salt: CB, drug combination  
 cetylpyridinium salt: CM, drug comparison  
 dodecyl sulfate sodium: CB, drug combination  
 dodecyl sulfate sodium: CM, drug comparison  
 hydroxymethylcellulose  
 hydroxypropylmethylcellulose: CM, drug comparison  
 hydroxypropylmethylcellulose: CB, drug combination  
 methylcellulose: CM, drug comparison  
 methylcellulose: CB, drug combination  
 polysorbate 20: CM, drug comparison  
 polysorbate 20: CB, drug combination  
 propylene glycol: CM, drug comparison  
 propylene glycol: CB, drug combination  
 surfactant: CM, drug comparison  
 surfactant: CB, drug combination  
 triethanolamine: CM, drug comparison  
 triethanolamine: CB, drug combination  
 unclassified drug  
 RN (benzalkonium) 8001-54-5; (carbopol 940) 76050-42-5;  
 (carboxymethylcellulose) 8050-38-2, 9000-11-7, 9004-32-4, 9050-04-8;  
 (cetrimide) 57-09-0, 6899-10-1, 8044-71-1; (cetylpyridinium salt)  
 123-03-5, 140-72-7, 2349-55-5, 7773-52-6; (dodecyl sulfate sodium)  
 151-21-3; (hydroxymethylcellulose) 37353-59-6;  
 (hydroxypropylmethylcellulose) 9004-65-3; (methylcellulose) 79484-92-7,  
 9004-67-5; (polysorbate 20) 12244-25-6, 9005-64-5; (propylene  
 glycol) 57-55-6; (triethanolamine) 102-71-6, 637-39-8  
 CN (1) Tween 20; (2) Metolose sm 4000; (3) Carbopol 940  
 CO (1) Merck; (2) Shinetsu; (3) Goodrich; Sigma; Ferak; Shima; Kasei

L73 ANSWER 10 OF 11 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 1988-101667 [15] WPIX  
 DNC C1988-045719  
 TI Azulene solns. - contain sodium or potassium hydrogen carbonate and alcohol e.g. ethanol to improve storage stability.  
 DC B05  
 PA (LIOY) LION CORP  
 CYC 1  
 PI JP 63051341 A 19880304 (198815)\* 6p  
 JP 07035342 B2 19950419 (199520) 5p C07C013-52  
 ADT JP 63051341 A JP 1986-194537 19860820; JP 07035342 B2 JP 1986-194537 19860820  
 FDT JP 07035342 B2 Based on JP 63051341  
 PRAI JP 1986-194537 19860820  
 IC A61K009-10; A61K031-01; C07C007-20; C07C013-52; C07C139-14; C07C143-22  
 ICM C07C013-52  
 ICS A61K031-01; C07C007-20; C07C139-14; C07C143-22; C07C303-42; C07C309-25  
 ICA A61K009-10; A61K031-015; A61K031-185  
 AB JP 63051341 A UPAB: 19930923  
 Azulene solns. contain hydrogen carbonate and 30-100 weight% alcohols for stabilising the azulenes, as solvents.  
 Quat. ammonium salt e.g. **cetylpyridinium chloride**, benzethonium chloride, benzalkonium chloride, may also be present.  
 Azulenes are pref. e.g. champ azulene (1,4-dimethyl-7-ethylazulene), guai azulene (1,4-dimethyl-7-isopropyl azulene). The amts. (against total compsns.) are pref. 0.1-0.5 weight%. As hydrogencarbonate, Na, K salts are pref., and their combined amts. are below 0.0001 weight%. As alcohols, ethanol, n-(iso)propanol, lauryl alcohol, etc., **propylene glycol**, glycerol, sorbitol, mannitol, glucose, PEG, (m.w. 400-1000) are used. The use amts. are pref. **40-60 wt** .%. The pref. combined amts. of the quat. ammonium salts are 0.01-1.0 weight%.

USE/ADVANTAGE - The stability of azulenes are raised remarkably, and no decomposition occurs at 40 deg. C, for 6 month storage. The quality of the preps. can be guaranteed.

In an example, compsn. comprises (unit; w/v %); azulene 0.3, NaHCO3 0.05, ethanol 50.0, benzethonium chloride 1.0, and purified H2O balance, (total 100.0). The residual % of azulene after storage at 40 deg. C, for 6 months is 99%.

O/O

FS CPI  
 FA AB; DCN  
 MC CPI: B05-C04; B10-J02; B12-M06; B12-M07

L73 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1972:117526 HCAPLUS

DN 76:117526

ED Entered STN: 12 May 1984

TI Gas-releasable and foamable compositions

IN Schmitt, William H.

PA Alberto-Culver Co.

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

IC A61R

NCL 424043000

CC 63 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3639568	A	19720201	US 1968-761876	19680923
PRAI	US 1968-761876		19680923		

AB Gas-releasable and foamable compns. (solids, liqs., pastes or gels) which can be packaged in nonpressurized containers, particularly collapsible tubes, contain 20 to 90 weight % of an anhydrous H2O-soluble organic solvent in which

is dissolved from 1 to 20 weight % of a compressible, H2O-insol. gas and any addnl. ingredients needed to complete the compns. for their intended uses (detergent tablets, suppositories, enemas, cleaners, cosmetics, etc.). The dissolved gas is released either as a gas or as a gas to form a foam when the compns. are wetted with H2O. A typical formulation contains polyethylene glycol 1000 45, polyethylene glycol 4000 45 and CCl3F 10% by **weight** and is used as a semisolid suppository. The glycols are melted at 60° and the gas added and mixed in a pressure vessel. After cooling the suppositories are formed by pressure molding. NaHCO3, NaCl, Na tartrate, Ca citrate and the sugar alcs. can be added to the composition to control the rate of release of the compressible gas.

ST gas release drug compn; foamable drug compn; suppository gas release compn

IT Pharmaceuticals

(gas-releasable)

IT 57-55-6, biological studies 75-69-4 78-78-4 123-03-5  
144-55-8, biological studies 151-21-3, biological studies 374-07-2  
1639-66-3 10025-06-6 25322-68-3

RL: BIOL (Biological study)

(in pharmaceuticals, gas-releasable)

=> => FILE USPATFUL

FILE 'USPATFULL' ENTERED AT 16:41:19 ON 26 MAR 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 25 Mar 2004 (20040325/PD)

FILE LAST UPDATED: 25 Mar 2004 (20040325/ED)

HIGHEST GRANTED PATENT NUMBER: US6711743

HIGHEST APPLICATION PUBLICATION NUMBER: US2004060089

CA INDEXING IS CURRENT THROUGH 25 Mar 2004 (20040325/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 25 Mar 2004 (20040325/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2004

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2004

```
>>> USPAT2 is now available.  USPATFULL contains full text of the  <<<
>>> original, i.e., the earliest published granted patents or  <<<
>>> applications.  USPAT2 contains full text of the latest US  <<<
>>> publications, starting in 2001, for the inventions covered in  <<<
>>> USPATFULL.  A USPATFULL record contains not only the original  <<<
>>> published document but also a list of any subsequent  <<<
>>> publications.  The publication number, patent kind code, and  <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.  <<<
```

```
>>> USPATFULL and USPAT2 can be accessed and searched together  <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to  <<<
>>> enter this cluster.  <<<
>>>  <<<
>>> Use USPATALL when searching terms such as patent assignees,  <<<
>>> classifications, or claims, that may potentially change from  <<<
>>> the earliest to the latest publication.  <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> D QUE

```
L22      6 SEA FILE=REGISTRY ABB=ON  (123-03-5/BI OR 56-81-5/BI OR
        57-55-6/BI OR 16969-45-2/BI OR 25322-68-3/BI OR 64-17-5/BI)
L23      1 SEA FILE=REGISTRY ABB=ON  L22 AND 1/CL
L24      1 SEA FILE=REGISTRY ABB=ON  "PROPYLENE GLYCOL"/CN
L74      57 SEA FILE=USPATFULL ABB=ON  L23 AND L24
L79      71 SEA FILE=USPATFULL ABB=ON  CETYLPYRIDINIUM(6A) (WT OR WEIGHT?)
L80      1 SEA FILE=USPATFULL ABB=ON  L74 AND L79
L81      180 SEA FILE=USPATFULL ABB=ON  CETYL PYRIDINIUM(6A) (WT OR WEIGHT?)

L82      0 SEA FILE=USPATFULL ABB=ON  L81 AND L74
L83      1 SEA FILE=USPATFULL ABB=ON  L80 OR L82
```

=> D L83 BIB HIT

L83 ANSWER 1 OF 1 USPATFULL on STN  
 AN 2003:237389 USPATFULL  
 TI Stable personal care compositions containing a retinoid  
 IN Resch, Bradley Steven, Cincinnati, OH, UNITED STATES  
 Zukowski, Joseph Michael, Cincinnati, OH, UNITED STATES  
 O'Donoghue, Margaret Ann, Monroe, OH, UNITED STATES  
 Smith, Shane Christian, Maineville, OH, UNITED STATES  
 PA THE PROCTER & GAMBLE COMPANY (U.S. corporation)  
 PI US 2003165546 A1 20030904  
 AI US 2002-90517 A1 20020304 (10)  
 DT Utility  
 FS APPLICATION  
 LREP THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON  
 HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI,  
 OH, 45224  
 CLMN Number of Claims: 26  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 1346  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 SUMM [0055] Non-limiting examples of quaternium ammonium compound  
 preservatives include benzalkonium chloride, benzethonium chloride, and  
 cetylpyridinium chloride. When present in compositions of the present  
 invention, benzalkonium chloride is preferably included in the  
 compositions of the present invention at a level from about 0.005% to  
 about 0.055%, by weight of the composition; benzethonium chloride  
 preferably from about 0.05% to about 0.25%, by **weight** of the  
 composition; and **cetylpyridinium** chloride preferably from  
 about 0.05% to about 1.05%, by weight of the composition.  
 IT 57-55-6, Propylene glycol, biological studies  
 (preservative enhancer; stable personal care compns. containing retinoid  
 and non-paraben preservative)  
 IT 54-21-7, Sodium salicylate 55-56-1, Chlorohexidine 57-11-4, Stearic  
 acid, biological studies 57-15-8, Chlorobutanol 59-50-7, Chlorocresol  
 60-33-3, Linoleic acid, biological studies 64-17-5, Ethanol, biological  
 studies 65-85-0D, Benzoic acid, C12-15 alkyl esters 68-26-8, Retinol  
 69-72-7, Salicylic acid, biological studies 79-81-2, Retinyl palmitate  
 88-04-0, Chloroxylenol 89-83-8, Thymol 90-43-7, o-Phenylphenol  
 101-20-2, Triclocarban 104-29-0 108-95-2, Phenol, biological studies  
 111-29-5, Pentyleneglycol 112-92-5, Stearyl alcohol 116-31-4,  
 Retinal 121-54-0, Benzethonium chloride **123-03-5**,  
 Cetylpyridinium chloride 127-47-9, Retinyl acetate 127-65-1,  
 Chloramine T 132-27-4, Sodium o-phenylphenol 302-79-4, Retinoic acid  
 499-44-5 532-32-1, Sodium benzoate 593-29-3, Potassium stearate  
 771-03-9, Dehydroacetic acid 994-36-5, Sodium citrate 1319-77-3,  
 Cresol 3380-34-5, Triclosan 4418-26-2, Sodium dehydroacetate  
 7069-42-3, Retinyl propionate 7211-53-2, Potassium behenate  
 7647-14-5, Sodium chloride, biological studies 7783-90-6, Silver  
 chloride, biological studies 11140-04-8, Glyceryl caprylate  
 13463-41-7, Zinc pyrithione 15421-15-5, Potassium ascorbate  
 18472-51-0, Chlorhexidine gluconate 24123-05-5D, N-alkylated  
 36653-82-4, Cetyl alcohol 66469-15-6, Potassium isostearate  
 148718-35-8, Octyl hydroxystearate  
 (stable personal care compns. containing retinoid and non-paraben  
 preservative)